Abstract: Described herein are new pharmaceutical formulations, their preparation, and their use for pain treatment. In particular, described herein are pharmaceutical formulations of the analgesic drug Nalbuphine for intranasal administration.

Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.

Abstract: Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated mangiferin includes adding a substance with fructosylating enzymatic activity to a transformed liquid containing mangiferin for biotransformation reaction, so as to convert the mangiferin into the fructosylated mangiferin, wherein the transformed liquid contains the mangiferin and a glycosyl donor; as well as a use of the fructosylated mangiferin in preparation of a medicament for treatment of tumor-related diseases.

Abstract: Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated mangiferin includes adding a substance with fructosylating enzymatic activity to a transformed liquid containing mangiferin for biotransformation reaction, so as to convert the mangiferin into the fructosylated mangiferin, wherein the transformed liquid contains the mangiferin and a glycosyl donor; as well as a use of the fructosylated mangiferin in preparation of a medicament for treatment of tumor-related diseases.

Abstract: Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

Abstract: Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.

Abstract: Described herein are methods for using macromolecular MRI contrast agents to evaluate the effectiveness of anti-cancer treatments. The methods take advantage of MRI for evaluating more specifically and accurately one or more tumor properties of the tumor in response to a particular treatment. Ultimately, the 5 methods described herein help evaluate the effectiveness of the anti-cancer treatment over time.